CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study (CHEMO-T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01719835

Recruitment Status : Unknown

Verified March 2018 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Active, not recruiting

First Posted : November 1, 2012

Last Update Posted : March 15, 2018

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Cancer Research UK

Information provided by (Responsible Party):

Royal Marsden NHS Foundation Trust

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Actual Primary Completion Date :	November 30, 2016
Estimated Study Completion Date :	August 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5.

To Top